AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
8.56
-0.30 (-3.39%)
At close: Aug 1, 2025, 4:00 PM
8.70
+0.14 (1.64%)
After-hours: Aug 1, 2025, 7:42 PM EDT
Smartsheet Revenue
In the fiscal year ending May 31, 2025, AngioDynamics had annual revenue of $292.50M, down -3.76%. AngioDynamics had revenue of $80.16M in the quarter ending May 31, 2025, with 12.93% growth.
Revenue (ttm)
$292.50M
Revenue Growth
-3.76%
P/S Ratio
1.20
Revenue / Employee
$433,330
Employees
675
Market Cap
347.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 292.50M | -11.42M | -3.76% |
| May 31, 2024 | 303.91M | -34.84M | -10.28% |
| May 31, 2023 | 338.75M | 22.53M | 7.13% |
| May 31, 2022 | 316.22M | 25.21M | 8.66% |
| May 31, 2021 | 291.01M | 26.85M | 10.17% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ANGO News
- 4 days ago - AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia - Business Wire
- 9 days ago - AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology - Business Wire
- 17 days ago - AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting - Benzinga
- 17 days ago - AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth - Business Wire
- 25 days ago - AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025 - Business Wire
- 5 weeks ago - AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism - Business Wire
- 4 months ago - Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance - Benzinga